Can budesonide be administered during an active Clostridioides difficile infection?

Budesonide Should NOT Be Given During Active C. difficile Infection

Budesonide and other corticosteroids should be avoided during active C. difficile infection (CDI) due to significant risk of worsening disease severity and mortality. 1, 2

Critical Safety Concerns

FDA Warning on Infection Risk

The FDA label for budesonide explicitly warns that corticosteroids suppress the immune system and can exacerbate existing infections 1. Specifically, the label states that corticosteroids can:

• Reduce resistance to new infections
• Exacerbate existing infections (directly applicable to active CDI)
• Increase risk of disseminated infections
• Mask signs of infection

The FDA recommends monitoring patients for infection development and considering discontinuation if infection occurs during treatment 1.

Direct Evidence of Harm in CDI

A 2023 preclinical study provides compelling evidence that budesonide specifically worsens CDI outcomes 2. In a murine model:

• Budesonide combined with fidaxomicin resulted in up to 90% mortality compared to 0% mortality with fidaxomicin alone
• All tested budesonide doses (0.02,0.1, and 10 mg/kg) worsened disease outcomes across all parameters (weight, survival, pathological scores)
• The study concluded that corticosteroid therapy may worsen the incidence and severity of CDI 2

Clinical Algorithm

If a patient has active CDI:

1. Discontinue budesonide immediately if currently prescribed
2. Treat CDI according to IDSA/SHEA 2021 guidelines with vancomycin or fidaxomicin 3
3. Do not restart budesonide until CDI is completely resolved and confirmed by clinical improvement

If a patient on budesonide develops CDI:

1. Stop budesonide (weigh against adrenal suppression risk if on chronic therapy)
2. Initiate appropriate CDI treatment
3. Consider stress-dose systemic corticosteroids only if patient has adrenal suppression concerns, but avoid if possible

If inflammatory bowel disease requires treatment during CDI:

1. Prioritize CDI treatment first with vancomycin 125 mg four times daily for 10 days 3
2. Delay resumption of immunosuppressive therapy until CDI resolves
3. Consider alternative IBD management strategies that don't involve corticosteroids

Important Caveats

Adrenal Suppression Risk

Patients on chronic budesonide therapy may have HPA axis suppression 1. Abrupt discontinuation requires careful assessment. If the patient is critically ill or undergoing surgery, supplementation with systemic glucocorticosteroids may be necessary despite CDI risk 1. This represents a clinical dilemma requiring individualized risk-benefit assessment with infectious disease consultation.

No Guideline Recommendation for Corticosteroids in CDI

The 2021 IDSA/SHEA guidelines make no mention of corticosteroids as adjunctive therapy for CDI 3. The treatment algorithm focuses exclusively on antibiotics (vancomycin, fidaxomicin, metronidazole), bezlotoxumab, and fecal microbiota transplantation. This absence is notable and suggests corticosteroids have no role in CDI management.

Distinction from Systemic Corticosteroids

While budesonide has lower systemic bioavailability than systemic corticosteroids, the FDA warnings apply to budesonide specifically 1, and the preclinical data demonstrate harm even with this "locally acting" corticosteroid 2.

The evidence converges: budesonide exacerbates C. difficile infection and should be discontinued during active disease.